Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or ...

AnaptysBio, Inc. has announced a Stock Repurchase Plan allowing for the buyback of up to $75 million of its common stock. As of the end of 2024, the company reports having over $420 million in ...

AnaptysBio, Inc. (ANAB) shares rallied 9.5% in the last trading session to close at $18.71. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

AnaptysBio shares rose 7.2% on a share-repurchase program authorized to buy back up to $75 million of the company's common stock. Shares were recently trading around $18.31. The stock is down 15% ...

(RTTNews) - AnaptysBio, Inc. (ANAB) on Monday announced that its Board of Directors has authorized a stock repurchase plan under which the company may repurchase up to $75 million of its ...

Investing.com -- Shares of AnaptysBio (NASDAQ:ANAB) climbed 12% today as the company announced a significant stock repurchase plan, signaling confidence in its financial position and future prospects.

Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 ...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its ...